AbbVie, a global pharmaceutical company, has completed its acquisition of Cerevel Therapeutics.
The strategic move by AbbVie allows the company to boost its clinical-stage pipeline across a number of neurological and psychiatric conditions, including schizophrenia, Parkinson’s disease and mood disorders. This includes:
- Emraclidine: A best-in-class antipsychotic, is a positive allosteric modulator of the M4 muscarinic receptor. It is currently being received in Phase II trials for the treatment of schizophrenia.
- Tavapadon: A dopamine, D1/D5 selective partial agonist, is currently in Phase III trials to determine its safety and efficacy in patients with Parkinson’s disease as both a monotherapy and an adjuvant for other standard of care treatments. The safety and efficacy exhibited in clinical trials thus far positions it as a great candidate for early Parkinson’s intervention, which can be used as an adjuvant to AbbVie’s current pipeline of late-stage drugs.
- CVL-354: Currently in Phase I, is a kappa opioid receptor antagonist that is being tested in patients with major depressive disorder (MDD).
- Darigabat: Currently in Phase II trials, is an alpha 2/3/5 selective GABAA receptor positive allosteric modulator for panic disorder and treatment-resistant epilepsy.
”AbbVie's acquisition of Cerevel strengthens our foundation in neuroscience and positions us to deliver sustainable long-term performance into the next decade and beyond," said CEO of AbbVie, Robert A. Michael. "Our new Cerevel colleagues share our commitment to deliver meaningful change for patients living with neurological and psychiatric conditions. We are excited to welcome the talented Cerevel team to AbbVie.”
